Lupin has completed the strategic spin-out of two oncology programs through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics Inc., a newly formed U.S.-based clinical-stage oncology company. According to Business Standard, the transaction was completed on July 20, 2026, with Lupin Inc. receiving an 82.2% equity stake valued at $1.6 million in return. Under the terms of the agreement, Lupin Inc. will provide exclusive perpetual rights to the programs and has received 332,000 common shares in Kaveri. Kaveri will advance these programs through global clinical trials, with the new company seeking external capital to finance its development efforts.
Kaveri will operate as an independent entity under the leadership of Chief Executive Officer Kristi Jones, a seasoned biopharmaceutical leader with experience in building and advancing drug-development companies. As reported by Business Standard, Chief Medical Officer Dr. Robert Pierce will bring deep clinical expertise and lead the company's clinical development strategy. Kaveri, incorporated in Delaware on May 20, 2026, is a clinical-stage oncology company focused on solid tumors including lung, pancreatic, ovarian, and CNS-related cancers. The company has no revenue or net worth at present and will seek to raise additional capital to fund its clinical development efforts.
Both programs have demonstrated encouraging clinical progress, with LNP7457 (PRMT5) and LNP8701 (SOS1) each reporting positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively. According to Business Standard, the experimental drugs are being studied in patients with advanced solid tumours - LNP7457 blocks a protein called PRMT5 that helps certain cancer cells grow, while LNP8701 targets the RAS signalling pathway associated with tumour growth. Kaveri will pursue biomarker-driven clinical development, explore combinations with other drugs, and focus on cancers for which patients have limited treatment options.
Lupin's stock reacted positively to the news, rising more than 1% in morning trade as reported by Business Standard. The move echoes earlier efforts by Indian drugmakers to place capital-intensive novel-drug research in specialized entities capable of attracting dedicated funding. Lupin CEO Vinita Gupta stated that the company is proud to have pioneered these oncology assets and looks forward to advancing them through Kaveri Therapeutics, positioning the strength of these assets with the company's seasoned leadership team to accelerate development of targeted oncology therapies. The structure allows Lupin to retain an economic interest in the assets while placing their capital-intensive global development under a separately funded oncology company.
